PDF herunterladen
Semin Thromb Hemost 2000; 26(5): 463-478
DOI: 10.1055/s-2000-13202
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

The Endothelium and Thrombosis

Peter L. Gross1 , William C. Aird1,2
  • 1Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • 2Department of Molecular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Dezember 2000 (online)

    Lizenzen und Reprints

ABSTRACT

Thrombosis reflects an imbalance between procoagulant and anticoagulant mechanisms. In some cases, thrombotic lesions are precipitated by gross changes in blood flow, vascular wall integrity, or systemic levels of coagulation factors. In other cases, thrombosis is induced by functional changes within the endothelium. Endothelial cells express a wide variety of factors that contribute to hemostasis, including procoagulants, anticoagulants, cell adhesion molecules, vasomotor substances, and cell survival signals. Because the endothelium displays a remarkable diversity of structure and function, the relative contribution of any one of these factors to the hemostatic balance varies between different vascular beds. In this review, we emphasize the heterogeneous nature of endothelial cell function. We then examine the role of endothelial diversity in modulating the phenotypic expression of thrombotic disorders.

KEYWORD

Thrombosis - endothelial cells - heterogeneity - hemostasis

REFERENCES

  • 1 Nawroth P P, Handley D, Stern D M. The multiple levels of endothelial cell-coagulation factor interactions.  Clin Haematol . 1986;  15 293-321
    PubMedGoogle Scholar
  • 2 Rodgers G M. Hemostatic properties of normal and perturbed vascular cells.  FASEB J . 1988;  2 116-123
    PubMedGoogle Scholar
  • 3 Bombeli T, Mueller M, Haeberli A. Anticoagulant properties of the vascular endothelium.  Thromb Haemost . 1997;  77 408-423
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Rosenberg R D, Aird W C. Vascular-bed-specific hemostasis and hypercoagulable states.  N Engl J Med . 1999;  340 1555-1564
    CrossrefPubMedGoogle Scholar
  • 5 Yamamoto K, de Waard V, Fearns C, Loskutoff D J. Tissue distribution and regulation of murine von Willebrand factor gene expression in vivo.  Blood . 1998;  92 2791-2801
    PubMedGoogle Scholar
  • 6 Yamamoto K, Loskutoff D J. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator.  J Clin Invest . 1996;  97 2440-2451
    CrossrefPubMedGoogle Scholar
  • 7 Østerud B, Bajaj M S, Bajaj S P. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue Factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH.  Thromb Haemost . 1995;  73 873-875
    PubMedGoogle Scholar
  • 8 Ishii H, Salem H H, Bell C E, Laposata E A, Majerus P W. Thrombomodulin, an endothelial anticoagulant protein, is absent from the human brain.  Blood . 1986;  67 362-365
    PubMedGoogle Scholar
  • 9 Drake T A, Cheng J, Chang A, Taylor Jr B F. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis [published erratum appears in Am J Pathol 1993;143:649].  Am J Pathol . 1993;  142 1458-1470
    PubMedGoogle Scholar
  • 10 Repo H, Harlan J M. Mechanisms and consequences of phagocyte adhesion to endothelium.  Ann Med . 1999;  31 156-165
    PubMedGoogle Scholar
  • 11 Eppihimer M J, Wolitzky B, Anderson D C, Labow M A, Granger D N. Heterogeneity of expression of E- and P-selectins in vivo.  Circ Res . 1996;  79 560-569
    PubMedGoogle Scholar
  • 12 McEver R P, Beckstead J H, Moore K L, Marshall-Carlson L, Bainton D F. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies.  J Clin Invest . 1989;  84 92-99
    PubMedGoogle Scholar
  • 13 Panes J, Perry M A, Anderson D C. Regional differences in constitutive and induced ICAM-1 expression in vivo.  Am J Physiol . 1995;  269 H1955-H1964
    PubMedGoogle Scholar
  • 14 Mulligan M S, Johnson K J, Todd R FD. Requirements for leukocyte adhesion molecules in nephrotoxic nephritis.  J Clin Invest . 1993;  91 577-587
    PubMedGoogle Scholar
  • 15 Mulligan M S, Lentsch A B, Shanley T P. Cytokine and adhesion molecule requirements for lung injury induced by anti-glomerular basement membrane antibody.  Inflammation . 1998;  22 403-417
    CrossrefPubMedGoogle Scholar
  • 16 Mulligan M S, Vaporciyan A A, Miyasaka M, Tamatani T, Ward P A. Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1.  Am J Pathol . 1993;  142 1739-1749
    PubMedGoogle Scholar
  • 17 Lopez S, Prats N, Marco A J. Expression of E-selectin, P-selectin, and intercellular adhesion molecule-1 during experimental murine listeriosis.  Am J Pathol . 1999;  155 1391-1397
    PubMedGoogle Scholar
  • 18 Guillot P V, Guan J, Liu L. A vascular bed-specific pathway.  J Clin Invest . 1999;  103 799-805
    PubMedGoogle Scholar
  • 19 Ursell P C, Mayes M. The majority of nitric oxide synthase in pig heart is vascular and not neural.  Cardiovasc Res . 1993;  27 1920-1924
    PubMedGoogle Scholar
  • 20 Pollock J S, Nakane M, Buttery L D. Characterization and localization of endothelial nitric oxide synthase using specific monoclonal antibodies.  Am J Physiol . 1993;  265 C1379-C1387
    PubMedGoogle Scholar
  • 21 Bachmann S, Bosse H M, Mundel P. Topography of nitric oxide synthesis by localizing constitutive NO synthases in mammalian kidney.  Am J Physiol . 1995;  268 F885-898
    PubMedGoogle Scholar
  • 22 Andries L J, Brutsaert D L, Sys S U. Nonuniformity of endothelial constitutive nitric oxide synthase distribution in cardiac endothelium.  Circ Res . 1998;  82 195-203
    PubMedGoogle Scholar
  • 23 Nadaud S, Philippe M, Arnal J F, Michel J B, Soubrier F. Sustained increase in aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high blood flow.  Circ Res . 1996;  79 857-863
    PubMedGoogle Scholar
  • 24 Everett A D, Le Cras D T, Xue C, Johns R A. eNOS expression is not altered in pulmonary vascular remodeling due to increased pulmonary blood flow.  Am J Physiol . 1998;  274 L1058-1065
    PubMedGoogle Scholar
  • 25 Shaul P W, Kinane B, Farrar M A, Buja L M, Magness R R. Prostacyclin production and mediation of adenylate cyclase activity in the pulmonary artery. Alterations after prolonged hypoxia in the rat.  J Clin Invest . 1991;  88 447-455
    PubMedGoogle Scholar
  • 26 Subramanian V A, Hernandez Y, Tack-Goldman K, Grabowski E F, Weksler B B. Prostacyclin production by internal mammary artery as a factor in coronary artery bypass grafts.  Surgery . 1986;  100 376-383
    PubMedGoogle Scholar
  • 27 Bombeli T, Karsan A, Tait J F, Harlan J M. Apoptotic vascular endothelial cells become procoagulant.  Blood . 1997;  89 2429-2442
    PubMedGoogle Scholar
  • 28 Polunovsky V A, Wendt C H, Ingbar D H, Peterson M S, Bitterman P B. Induction of endothelial cell apoptosis by TNF alpha: Modulation by inhibitors of protein synthesis.  Exp Cell Res . 1994;  214 584-594
    CrossrefPubMedGoogle Scholar
  • 29 Meredith Jr E J, Fazeli B, Schwartz M A. The extracellular matrix as a cell survival factor.  Mol Biol Cell . 1993;  4 953-961
    PubMedGoogle Scholar
  • 30 Re F, Zanetti A, Sironi M. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells.  J Cell Biol . 1994;  127 537-546
    CrossrefPubMedGoogle Scholar
  • 31 Bach F H, Ferran C, Hechenleitner P. Accommodation of vascularized xenografts: Expression of ``protective genes'' by donor endothelial cells in a host Th2 cytokine environment.  Nat Med . 1997;  3 196-204
    CrossrefPubMedGoogle Scholar
  • 32 Bach F H, Hancock W W, Ferran C. Protective genes expressed in endothelial cells: A regulatory response to injury.  Immunol Today . 1997;  18 483-486
    CrossrefPubMedGoogle Scholar
  • 33 Zwaal R F, Schroit A J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells.  Blood . 1997;  89 1121-1132
    PubMedGoogle Scholar
  • 34 Gimbrone Jr A M. Vascular endothelium: An integrator of pathophysiologic stimuli in atherosclerosis.  Am J Cardiol . 1995;  75 67B-70B
    CrossrefPubMedGoogle Scholar
  • 35 Anderson T J, Gerhard M D, Meredith I T. Systemic nature of endothelial dysfunction in atherosclerosis.  Am J Cardiol . 1995;  75 71B-74B
    CrossrefPubMedGoogle Scholar
  • 36 Blann A D, Lip G Y. The endothelium in atherothrombotic disease: Assessment of function, mechanisms and clinical implications.  Blood Coagul Fibrinolysis . 1998;  9 297-306
    PubMedGoogle Scholar
  • 37 Cines D B, Pollak E S, Buck C A. Endothelial cells in physiology and in the pathophysiology of vascular disorders.  Blood . 1998;  91 3527-3561
    PubMedGoogle Scholar
  • 38 Falanga A, Rickles F R. Pathophysiology of the thrombophilic state in the cancer patient.  Semin Thromb Hemost . 1999;  25 173-182
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 39 Guba S C, Fonseca V, Fink L M. Hyperhomocysteinemia and thrombosis.  Semin Thromb Hemost . 1999;  25 291-309
    PubMedGoogle Scholar
  • 40 Upchurch Jr R G, Welch G N, Fabian A J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase.  J Biol Chem . 1997;  272 17012-17017
    CrossrefPubMedGoogle Scholar
  • 41 Chow K, Cheung F, Lao T T, Karmin O. Effect of homocysteine on the production of nitric oxide in endothelial cells.  Clin Exp Pharmacol Physiol . 1999;  26 817-818
    CrossrefPubMedGoogle Scholar
  • 42 Lentz S R, Sadler J E. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.  J Clin Invest . 1991;  88 1906-1914
    PubMedGoogle Scholar
  • 43 Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells.  J Clin Invest . 1993;  92 1381-1386
    PubMedGoogle Scholar
  • 44 Fryer R H, Wilson B D, Gubler D B, Fitzgerald L A, Rodgers G M. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells.  Arterioscler Thromb . 1993;  13 1327-1333
    PubMedGoogle Scholar
  • 45 Wang H, Yoshizumi M, Lai K. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine.  J Biol Chem . 1997;  272 25380-25385
    CrossrefPubMedGoogle Scholar
  • 46 Lee M E, Wang H. Homocysteine and hypomethylation.  A novel link to vascular disease. Trends Cardiovasc Med . 1999;  9 49-54
    PubMedGoogle Scholar
  • 47 Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats.  FASEB J . 1997;  11 1157-1168
    PubMedGoogle Scholar
  • 48 Lentz S R, Sobey C G, Piegors D J. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia.  J Clin Invest . 1996;  98 24-29
    PubMedGoogle Scholar
  • 49 Van den Berg M, Boers G H, Franken D G. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease.  Eur J Clin Invest . 1995;  25 176-181
    PubMedGoogle Scholar
  • 50 Freyburger G, Labrouche S, Sassoust G. Mild hyperhomocysteinemia and hemostatic factors in patients with arterial vascular diseases.  Thromb Haemost . 1997;  77 466-471
    PubMedGoogle Scholar
  • 51 Aster R H. Heparin-induced thrombocytopenia and thrombosis [editorial; comment].  N Engl J Med . 1995;  332 1374-1376
    CrossrefPubMedGoogle Scholar
  • 52 Visentin G P, Ford S E, Scott J P, Aster R H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.  J Clin Invest . 1994;  93 81-88
    CrossrefPubMedGoogle Scholar
  • 53 Herbert J M, Savi P, Jeske W P, Walenga J M. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells.  Thromb Haemost . 1998;  80 326-331
    PubMedGoogle Scholar
  • 54 Warkentin T E, Hayward C P, Boshkov L K. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia.  Blood . 1994;  84 3691-3699
    CrossrefPubMedGoogle Scholar
  • 55 Barry O P, FitzGerald G A. Mechanisms of cellular activation by platelet microparticles.  Thromb Haemost . 1999;  82 794-800
    PubMedGoogle Scholar
  • 56 Cines D B, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia.  N Engl J Med . 1987;  316 581-589
    CrossrefPubMedGoogle Scholar
  • 57 Kwaan H C, Sakurai S. Endothelial cell hyperplasia contributes to thrombosis in heparin-induced thrombocytopenia.  Semin Thromb Hemost . 1999;  25 23-27
    PubMedGoogle Scholar
  • 58 Makhoul R G, Greenberg C S, McCann R L. Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution.  J Vasc Surg . 1986;  4 522-528
    PubMedGoogle Scholar
  • 59 Boshkov L K, Warkentin T E, Hayward C P, Andrew M, Kelton J G. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies.  Br J Haematol . 1993;  84 322-328
    PubMedGoogle Scholar
  • 60 Groger M, Sarmay G, Fiebiger E, Wolff K, Petzelbauer P. Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro.  J Immunol . 1996;  156 1549-1556
    PubMedGoogle Scholar
  • 61 Warkentin T E. Heparin-induced skin lesions.  Br J Haematol . 1996;  92 494-497
    CrossrefPubMedGoogle Scholar
  • 62 Asherson R A, Khamashta M A, Ordi-Ros J. The ``primary'' antiphospholipid syndrome: Major clinical and serological features.  Medicine (Baltimore) . 1989;  68 366-374
    PubMedGoogle Scholar
  • 63 Finazzi G, Brancaccio V, Moia M. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry.  Am J Med . 1996;  100 530-536
    CrossrefPubMedGoogle Scholar
  • 64 Bick R L, Baker W F. Antiphospholipid syndrome and thrombosis.  Semin Thromb Hemost . 1999;  25 333-350
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 65 Greaves M. Antiphospholipid antibodies and thrombosis.  Lancet . 1999;  353 1348-1353
    CrossrefPubMedGoogle Scholar
  • 66 Simantov R, Lo S K, Gharavi A. Antiphospholipid antibodies activate vascular endothelial cells.  Lupus . 1996;  5 440-441
    PubMedGoogle Scholar
  • 67 McCrae K R, DeMichele A, Samuels P. Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies.  Br J Haematol . 1991;  79 595-605
    PubMedGoogle Scholar
  • 68 Matsuda J, Gotoh M, Gohchi K. Anti-endothelial cell antibodies to the endothelial hybridoma cell line (EAhy926) in systemic lupus erythematosus patients with antiphospholipid antibodies.  Br J Haematol . 1997;  97 227-232
    CrossrefPubMedGoogle Scholar
  • 69 Hill M B, Phipps J L, Malia R G, Greaves M, Hughes P. Characterization and specificity of anti-endothelial cell membrane antibodies and their relationship to thrombosis in primary antiphospholipid syndrome (APS).  Clin Exp Immunol . 1995;  102 368-372
    PubMedGoogle Scholar
  • 70 Arnout J. The pathogenesis of the antiphospholipid syndrome: A hypothesis based on parallelisms with heparin-induced thrombocytopenia.  Thromb Haemost . 1996;  75 536-541
    PubMedGoogle Scholar
  • 71 Combes V, Simon A C, Grau G E. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant.  J Clin Invest . 1999;  104 93-102
    CrossrefPubMedGoogle Scholar
  • 72 Martinuzzo M E, Maclouf J, Carreras L O, Levy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation.  Thromb Haemost . 1993;  70 667-671
    PubMedGoogle Scholar
  • 73 Lin Y L, Wang C T. Activation of human platelets by the rabbit anticardiolipin antibodies.  Blood . 1992;  80 3135-3143
    PubMedGoogle Scholar
  • 74 Lindsey N J, Henderson F I, Malia R, Milford-Ward M A, Greaves M, Hughes P. Inhibition of prostacyclin release by endothelial binding anticardiolipin antibodies in thrombosis-prone patients with systemic lupus erythematosus and the antiphospholipid syndrome.  Br J Rheumatol . 1994;  33 20-26
    PubMedGoogle Scholar
  • 75 Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras L O. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant.  Blood . 1991;  78 2894-2899
    PubMedGoogle Scholar
  • 76 Marciniak E, Romond E H. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant.  Blood . 1989;  74 2426-2432
    CrossrefPubMedGoogle Scholar
  • 77 Malia R G, Kitchen S, Greaves M, Preston F E. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies.  Br J Haematol . 1990;  76 101-107
    CrossrefPubMedGoogle Scholar
  • 78 Oosting J D, Preissner K T, Derksen R H, de Groot G P. Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro.  Br J Haematol . 1993;  85 761-768
    PubMedGoogle Scholar
  • 79 Shibata S, Harpel P C, Gharavi A, Rand J, Fillit H. Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes.  Blood . 1994;  83 2532-2540
    CrossrefPubMedGoogle Scholar
  • 80 Tsakiris D A, Marbet G A, Makris P E, Settas L, Duckert F. Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant.  Thromb Haemost . 1989;  61 175-177
    PubMedGoogle Scholar
  • 81 Pierangeli S S, Colden-Stanfield M, Liu X, Barker J H, Anderson G L, Harris E N. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo.  Circulation . 1999;  99 1997-2002
    CrossrefPubMedGoogle Scholar
  • 82 Simantov R, LaSala J M, Lo S K. Activation of cultured vascular endothelial cells by antiphospholipid antibodies.  J Clin Invest . 1995;  96 2211-2219
    CrossrefPubMedGoogle Scholar
  • 83 George J, Blank M, Levy Y. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome.  Circulation . 1998;  97 900-906
    PubMedGoogle Scholar
  • 84 Branch D W, Rodgers G M. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis.  Am J Obstet Gynecol . 1993;  168 206-210
    CrossrefPubMedGoogle Scholar
  • 85 Bordron A, Dueymes M, Levy Y. The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis.  J Clin Invest . 1998;  101 2029-2035
    PubMedGoogle Scholar
  • 86 Nakamura N, Ban T, Yamaji K, Yoneda Y, Wada Y. Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset.  J Clin Invest . 1998;  101 1951-1959
    PubMedGoogle Scholar
  • 87 Ferro D, Pittoni V, Quintarelli C. Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state.  Circulation . 1997;  95 1425-1432
    PubMedGoogle Scholar
  • 88 Atsumi T, Khamashta M A, Haworth R S. Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1.  Arthritis Rheum . 1998;  41 800-807
    CrossrefPubMedGoogle Scholar
  • 89 Hill M B, Phipps J L, Hughes P, Greaves M. Anti-endothelial cell antibodies in primary antiphospholipid syndrome and SLE: patterns of reactivity with membrane antigens on microvascular and umbilical venous cell membranes.  Br J Haematol . 1998;  103 416-421
    CrossrefPubMedGoogle Scholar
  • 90 Cuadrado M J, Tinahones F, Camps M T. Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome.  QJM . 1998;  91 619-626
    CrossrefPubMedGoogle Scholar
  • 91 Harats D, George J, Levy Y. Atheroma: links with antiphospholipid antibodies, Hughes syndrome and lupus.  QJM . 1999;  92 57-59
    CrossrefPubMedGoogle Scholar
  • 92 Hillmen P, Lewis S M, Bessler M, Luzzatto L, Dacie J V. Natural history of paroxysmal nocturnal hemoglobinuria.  N Engl J Med . 1995;  333 1253-1258
    CrossrefPubMedGoogle Scholar
  • 93 Socie G, Mary J Y, de Gramont A. Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors. French Society of Haematology.  Lancet . 1996;  348 573-577
    CrossrefPubMedGoogle Scholar
  • 94 Rosse W F. Paroxysmal nocturnal hemoglobinuria as a molecular disease.  Medicine (Baltimore) . 1997;  76 63-93
    CrossrefPubMedGoogle Scholar
  • 95 Hugel B, Socie G, Vu T. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia.  Blood . 1999;  93 3451-3456
    PubMedGoogle Scholar
  • 96 Brooimans R A, van Wieringen A P, van Es A L, Daha M R. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.  Eur J Immunol . 1992;  22 3135-3140
    PubMedGoogle Scholar
  • 97 Brooimans R A, Van der Ark A A, Tomita M, Van Es A L, Daha M R. CD59 expressed by human endothelial cells functions as a protective molecule against complement-mediated lysis.  Eur J Immunol . 1992;  22 791-797
    PubMedGoogle Scholar
  • 98 Mason J C, Yarwood H, Sugars K. Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition.  Blood . 1999;  94 1673-1682
    PubMedGoogle Scholar
  • 99 Saadi S, Holzknecht R A, Patte C P, Stern D M, Platt J L. Complement-mediated regulation of tissue factor activity in endothelium.  J Exp Med . 1995;  182 1807-1814
    CrossrefPubMedGoogle Scholar
  • 100 Tedesco F, Pausa M, Nardon E. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity.  J Exp Med . 1997;  185 1619-1627
    CrossrefPubMedGoogle Scholar
  • 101 Foreman K E, Vaporciyan A A, Bonish B K. C5a-induced expression of P-selectin in endothelial cells.  J Clin Invest . 1994;  94 1147-1155
    CrossrefPubMedGoogle Scholar
  • 102 Lozada C, Levin R I, Huie M. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1.  Proc Natl Acad Sci USA . 1995;  92 8378-8382
    PubMedGoogle Scholar
  • 103 Kilgore K S, Shen J P, Miller B F, Ward P A, Warren J S. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM- 1.  J Immunol . 1995;  155 1434-1441
    PubMedGoogle Scholar
  • 104 Hattori R, Hamilton K K, McEver R P, Sims P J. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface.  J Biol Chem . 1989;  264 9053-9060
    PubMedGoogle Scholar
  • 105 Hamilton K K, Hattori R, Esmon C T, Sims P J. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex.  J Biol Chem . 1990;  265 3809-3814
    PubMedGoogle Scholar
  • 106 Takahashi T, Kalka C, Masuda H. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization.  Nature Med . 1999;  5 434-438
    PubMedGoogle Scholar
  • 107 Asahara T, Masuda H, Takahashi T. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.  Circ Res . 1999;  85 221-228
    CrossrefPubMedGoogle Scholar
  • 108 Asahara T, Takahashi T, Masuda H. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells.  EMBO J . 1999;  18 3964-3972
    CrossrefPubMedGoogle Scholar
  • 109 Cano-Gauci D F, Song H H, Yang H. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome.  J Cell Biol . 1999;  146 255-264
    PubMedGoogle Scholar
  • 110 Veugelers M, De Cat B, Ceulemans H. Glypican-6, a new member of the glypican family of cell surface heparan sulfate proteoglycans.  J Biol Chem . 1999;  274 26968-26977
    CrossrefPubMedGoogle Scholar
  • 111 Gartner Jr C J, Hashida Y, O'Gorman M, Jaffe R. Endothelial proliferation in paroxysmal nocturnal hemoglobinuria.  Pediatr Pathol . 1988;  8 313-320
    PubMedGoogle Scholar
  • 112 Dunphy C H, Sotelo-Avila C, Luisiri A, Chu J Y. Paroxysmal nocturnal hemoglobinuria associated with venous thrombosis and papillary endothelial hyperplasia presenting as ulcerated duodenal mass.  Arch Pathol Lab Med . 1994;  118 837-839
    PubMedGoogle Scholar
  • 113 Francis Jr B R. Elevated fibrin D-dimer fragment in sickle cell anemia: Evidence for activation of coagulation during the steady state as well as in painful crisis.  Haemostasis . 1989;  19 105-111
    PubMedGoogle Scholar
  • 114 Devine D V, Kinney T R, Thomas P F, Rosse W F, Greenberg C S. Fragment D-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease.  Blood . 1986;  68 317-319
    PubMedGoogle Scholar
  • 115 Kurantsin-Mills J, Ofosu F A, Safa T K, Siegel R S, Lessin L S. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients.  Br J Haematol . 1992;  81 539-544
    CrossrefPubMedGoogle Scholar
  • 116 Hebbel R P, Boogaerts M A, Eaton J W, Steinberg M H. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity.  N Engl J Med . 1980;  302 992-995
    PubMedGoogle Scholar
  • 117 Mohandas N, Evans E. Adherence of sickle erythrocytes to vascular endothelial cells: Requirement for both cell membrane changes and plasma factors.  Blood . 1984;  64 282-287
    PubMedGoogle Scholar
  • 118 Manodori A B, Matsui N M, Chen J Y, Embury S H. Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation.  Blood . 1998;  92 3445-3454
    PubMedGoogle Scholar
  • 119 Hebbel R P. Perspectives series: Cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium.  J Clin Invest . 1997;  99 2561-2564
    PubMedGoogle Scholar
  • 120 Barabino G A, McIntire L V, Eskin S G, Sears D A, Udden M. Endothelial cell interactions with sickle cell, sickle trait, mechanically injured, and normal erythrocytes under controlled flow.  Blood . 1987;  70 152-157
    PubMedGoogle Scholar
  • 121 Kaul D K, Fabry M E, Nagel R L. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: Pathophysiological implications.  Proc Natl Acad Sci USA . 1989;  86 3356-3360
    PubMedGoogle Scholar
  • 122 Kaul D K, Fabry M E, Costantini F, Rubin E M, Nagel R L. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse.  J Clin Invest . 1995;  96 2845-2853
    PubMedGoogle Scholar
  • 123 Sultana C, Shen Y, Rattan V, Johnson C, Kalra V K. Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes.  Blood . 1998;  92 3924-3935
    PubMedGoogle Scholar
  • 124 Phelan M, Perrine S P, Brauer M, Faller D V. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture.  J Clin Invest . 1995;  96 1145-1151
    PubMedGoogle Scholar
  • 125 Smolinski P A, Offermann M K, Eckman J R, Wick T M. Double-stranded RNA induces sickle erythrocyte adherence to endothelium: A potential role for viral infection in vaso-occlusive pain episodes in sickle cell anemia.  Blood . 1995;  85 2945-2950
    PubMedGoogle Scholar
  • 126 Hebbel R P, Vercellotti G M. The endothelial biology of sickle cell disease.  J Lab Clin Med . 1997;  129 288-293
    CrossrefPubMedGoogle Scholar
  • 127 Liu X W, Pierangeli S S, Barker J, Wick T M, Hsu L L. RBC adhesion to cremaster endothelium in mice with abnormal hemoglobin is increased by topical endotoxin.  Ann N Y Acad Sci . 1998;  850 391-393
    PubMedGoogle Scholar
  • 128 Sowemimo-Coker S O, Meiselman H J, Francis Jr B R. Increased circulating endothelial cells in sickle cell crisis.  Am J Hematol . 1989;  31 263-265
    PubMedGoogle Scholar
  • 129 Solovey A, Lin Y, Browne P. Circulating activated endothelial cells in sickle cell anemia.  N Engl J Med . 1997;  337 1584-1590
    CrossrefPubMedGoogle Scholar
  • 130 Solovey A, Gui L, Key N S, Hebbel R P. Tissue factor expression by endothelial cells in sickle cell anemia.  J Clin Invest . 1998;  101 1899-1904
    CrossrefPubMedGoogle Scholar
  • 131 Stuart M J, Setty B N. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment.  Blood . 1999;  94 1555-1560
    PubMedGoogle Scholar
  • 132 Stockman J A, Nigro M A, Mishkin M M, Oski F A. Occlusion of large cerebral vessels in sickle-cell anemia.  N Engl J Med . 1972;  287 846-849
    PubMedGoogle Scholar
  • 133 Russell M O, Goldberg H I, Hodson A. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease.  Blood . 1984;  63 162-169
    PubMedGoogle Scholar
  • 134 Brittain H A, Eckman J R, Wick T M. Sickle erythrocyte adherence to large vessel and microvascular endothelium under physiologic flow is qualitatively different.  J Lab Clin Med . 1992;  120 538-545
    PubMedGoogle Scholar
  • 135 Weiler-Guettler H, Christie P D, Beeler D L. A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state.  J Clin Invest . 1998;  101 1983-1991
    CrossrefPubMedGoogle Scholar
  • 136 Ohlin A K, Marlar R A. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease.  Blood . 1995;  85 330-336
    PubMedGoogle Scholar
  • 137 Ireland H, Kunz G, Kyriakoulis K, Stubbs P J, Lane D A. Thrombomodulin gene mutations associated with myocardial infarction.  Circulation . 1997;  96 15-18
    PubMedGoogle Scholar
  • 138 Doggen C J, Kunz G, Rosendaal F R. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men.  Thromb Haemost . 1998;  80 743-748
    PubMedGoogle Scholar
  • 139 Le Flem L, Picard V, Emmerich J. Mutations in promoter region of thrombomodulin and venous thromboembolic disease.  Arterioscler Thromb Vasc Biol . 1999;  19 1098-1104
    PubMedGoogle Scholar
  • 140 Stegnar M, Uhrin P, Peternel P. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism.  Thromb Haemost . 1998;  79 975-979
    PubMedGoogle Scholar
  • 141 Margaglione M, Cappucci G, Colaizzo D. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease.  Arterioscler Thromb Vasc Biol . 1998;  18 152-156
    PubMedGoogle Scholar
  • 142 Shimasaki Y, Yasue H, Yoshimura M. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction.  J Am Coll Cardiol . 1998;  31 1506-1510
    CrossrefPubMedGoogle Scholar
  • 143 Hibi K, Ishigami T, Tamura K. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction.  Hypertension . 1998;  32 521-526
    PubMedGoogle Scholar
  • 144 Hingorani A D, Liang C F, Fatibene J. A common variant of the endothelial nitric oxide synthase (Glu298 ?.  Asp) is a major risk factor for coronary artery disease in the UK. Circulation . 1999;  100 1515-1520
    PubMedGoogle Scholar
  • 145 Philip I, Plantefeve G, Vuillaumier-Barrot S. G894T polymorphism in the endothelial nitric oxide synthase gene is associated with an enhanced vascular responsiveness to phenylephrine.  Circulation . 1999;  99 3096-3098
    PubMedGoogle Scholar
  • 146 Wang X L, Sim A S, Badenhop R F, McCredie R M, Wilcken D E. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene.  Nature Med . 1996;  2 41-45
    CrossrefPubMedGoogle Scholar
  • 147 Miyata T, Sakata T, Kumeda K. C-399T polymorphism in the promoter region of human tissue factor pathway inhibitor (TFPI) gene does not change the plasma TFPI antigen level and does not cause venous thrombosis [letter].  Thromb Haemost . 1998;  80 345-346
    PubMedGoogle Scholar
  • 148 Moatti D, Seknadji P, Galand C. Polymorphisms of the tissue factor pathway inhibitor (TFPI) gene in patients with acute coronary syndromes and in healthy subjects: Impact of the V264M substitution on plasma levels of TFPI.  Arterioscler Thromb Vasc Biol . 1999;  19 862-869
    PubMedGoogle Scholar
  • 149 Arnaud E, Moatti D, Emmerich J, Aiach M, de Prost D. No link between the TFPI V264M mutation and venous thromboembolic disease [letter].  Thromb Haemost . 1999;  82 159-160
    PubMedGoogle Scholar
  • 150 Carlsson L E, Santoso S, Baurichter G. Heparin-induced thrombocytopenia: New insights into the impact of the FcgammaRIIa-R-H131 polymorphism.  Blood . 1998;  92 1526-1531
    PubMedGoogle Scholar
  • 151 Moake J L, Chow T W. Thrombotic thrombocytopenic purpura: Understanding a disease no longer rare.  Am J Med Sci . 1998;  316 105-119
    PubMedGoogle Scholar
  • 152 Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen.  Thromb Res . 1985;  38 469-479
    CrossrefPubMedGoogle Scholar
  • 153 Ridolfi R L, Bell W R. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature.  Medicine (Baltimore) . 1981;  60 413-428
    PubMedGoogle Scholar
  • 154 Koenig D W, Barley-Maloney L, Daniel T O. A Western blot assay detects autoantibodies to cryptic endothelial antigens in thrombotic microangiopathies.  J Clin Immunol . 1993;  13 204-211
    CrossrefPubMedGoogle Scholar
  • 155 Tandon N N, Rock G, Jamieson G A. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura.  Br J Haematol . 1994;  88 816-825
    CrossrefPubMedGoogle Scholar
  • 156 Umibe T, Nawata Y, Mori N. [Thrombotic thrombocytopenic purpura (TTP) observed in a patient with primary antiphospholipid antibody syndrome].  Ryumachi . 1994;  34 981-987
    PubMedGoogle Scholar
  • 157 del Arco A, Martinez M A, Pena J M. Thrombotic thrombocytopenic purpura associated with human immunodeficiency virus infection: Demonstration of p24 antigen in endothelial cells.  Clin Infect Dis . 1993;  17 360-363
    PubMedGoogle Scholar
  • 158 Noris M, Ruggenenti P, Todeschini M. Increased nitric oxide formation in recurrent thrombotic microangiopathies: A possible mediator of microvascular injury.  Am J Kidney Dis . 1996;  27 790-796
    PubMedGoogle Scholar
  • 159 Wada H, Ohiwa M, Kaneko T. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation.  Am J Hematol . 1992;  39 20-24
    PubMedGoogle Scholar
  • 160 Wada H, Minamikawa K, Wakita Y. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation.  Am J Hematol . 1993;  44 85-88
    PubMedGoogle Scholar
  • 161 Kobayashi M, Wada H, Wakita Y. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura.  Thromb Haemost . 1995;  73 10-14
    PubMedGoogle Scholar
  • 162 Mitra D, Jaffe E A, Weksler B. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells.  Blood . 1997;  89 1224-1234
    PubMedGoogle Scholar
  • 163 Moake J L. Haemolytic-uraemic syndrome: Basic science.  Lancet . 1994;  343 393-397
    CrossrefPubMedGoogle Scholar
  • 164 Obrig T G, Louise C B, Lingwood C A. Endothelial heterogeneity in Shiga toxin receptors and responses.  J Biol Chem . 1993;  268 15484-15488
    PubMedGoogle Scholar
  • 165 Jennette J C, Falk R J. Small-vessel vasculitis.  N Engl J Med . 1997;  337 1512-1523
    CrossrefPubMedGoogle Scholar
  • 166 Belmont H M, Abramson S B, Lie J T. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium.  Arthritis Rheum . 1996;  39 9-22
    CrossrefPubMedGoogle Scholar
  • 167 Boehme M W, Nawroth P P, Kling E. Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus.  Arthritis Rheum . 1994;  37 572-577
    PubMedGoogle Scholar
  • 168 Boehme M W, Schmitt W H, Youinou P, Stremmel W R, Gross W L. Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides.  Am J Med . 1996;  101 387-394
    CrossrefPubMedGoogle Scholar
  • 169 D'Cruz D, Direskeneli H, Khamashta M, Hughes G R. Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: Potential markers for disease activity.  J Rheumatol . 1999;  26 103-109
    PubMedGoogle Scholar
  • 170 Herrick A L, Illingworth K, Blann A. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.  Ann Rheum Dis . 1996;  55 122-127
    PubMedGoogle Scholar
  • 171 Wang C R, Liu M F, Tsai R T, Chuang C Y, Chen C Y. Circulating intercellular adhesion molecules-1 and autoantibodies including anti-endothelial cell, anti-cardiolipin, and anti-neutrophil cytoplasma antibodies in patients with vasculitis.  Clin Rheumatol . 1993;  12 375-380
    PubMedGoogle Scholar
  • 172 Sneller M C, Fauci A S. Pathogenesis of vasculitis syndromes.  Med Clin North Am . 1997;  81 221-242
    PubMedGoogle Scholar
  • 173 Ferraro G, Meroni P L, Tincani A. Anti-endothelial cell antibodies in patients with Wegener's granulomatosis and micropolyarteritis.  Clin Exp Immunol . 1990;  79 47-53
    PubMedGoogle Scholar
  • 174 Leung D Y, Collins T, Lapierre L A, Geha R S, Pober J S. Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon.  J Clin Invest . 1986;  77 1428-1435
    PubMedGoogle Scholar
  • 175 del Papa N, Meroni P L, Barcellini W. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells.  Clin Immunol Immunopathol . 1992;  63 267-274
    CrossrefPubMedGoogle Scholar
  • 176 Kobold A C, van Wijk T R, Franssen C F. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener's granulomatosis and microscopic polyangiitis.  Clin Exp Rheumatol . 1999;  17 433-440
    PubMedGoogle Scholar
  • 177 Boom B W, Mommaas M, Daha M R, Vermeer B J. Complement-mediated endothelial cell damage in immune complex vasculitis of the skin: Ultrastructural localization of the membrane attack complex.  J Invest Dermatol . 1989;  93 68S-72S
    CrossrefPubMedGoogle Scholar
  • 178 Suttorp N, Bhakdi S. Terminal complement complex and endothelial cells.  Z Kardiol . 1989;  78 140-142
    PubMedGoogle Scholar
  • 179 Mayet W J, Schwarting A, Orth T. Signal transduction pathways of membrane expression of proteinase 3 (PR- 3) in human endothelial cells.  Eur J Clin Invest . 1997;  27 893-899
    CrossrefPubMedGoogle Scholar
  • 180 De Bandt M, Meyer O, Dacosta L, Elbim C, Pasquier C. Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane.  Clin Exp Immunol . 1999;  115 362-368
    CrossrefPubMedGoogle Scholar
  • 181 Sibelius U, Hattar K, Schenkel A. Wegener's granulomatosis: Anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response.  J Exp Med . 1998;  187 497-503
    CrossrefPubMedGoogle Scholar
  • 182 de Bandt M, Ollivier V, Meyer O. Induction of interleukin-1 and subsequent tissue factor expression by anti-proteinase 3 antibodies in human umbilical vein endothelial cells.  Arthritis Rheum . 1997;  40 2030-2038
    PubMedGoogle Scholar
  • 183 Mayet W J, Meyer zum Büschenfelde K H. Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells.  Clin Exp Immunol . 1993;  94 440-446
    PubMedGoogle Scholar
  • 184 Yang J J, Kettritz R, Falk R J, Jennette J C, Gaido M L. Apoptosis of endothelial cells induced by the neutrophil serine proteases proteinase 3 and elastase.  Am J Pathol . 1996;  149 1617-1626
    PubMedGoogle Scholar
  • 185 Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells.  Blood . 1989;  74 222-228
    PubMedGoogle Scholar
  • 186 Anrather D, Millan M T, Palmetshofer A. Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF.  J Immunol . 1997;  159 5620-5628
    PubMedGoogle Scholar
  • 187 Golden C L, Nick H S, Visner G A. Thrombin regulation of endothelin-1 gene in isolated human pulmonary endothelial cells.  Am J Physiol . 1998;  274 L854-L863
    PubMedGoogle Scholar
  • 188 Kaplanski G, Marin V, Fabrigoule M. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1; CD54) and vascular cell adhesion molecule-1 (VCAM-1; CD106).  Blood . 1998;  92 1259-1267
    PubMedGoogle Scholar
  • 189 Tsopanoglou N E, Maragoudakis M E. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors.  J Biol Chem. 1999;  274 23969-23976
    CrossrefPubMedGoogle Scholar
  • 190 Nagy Z, Kolev K, Csonka E, Pek M, Machovich R. Contraction of human brain endothelial cells induced by thrombogenic and fibrinolytic factors. An in vitro cell culture model.  Stroke . 1995;  26 265-270
    PubMedGoogle Scholar
  • 191 Itoh Y, Tomita M, Tanahashi N. Platelet adhesion to aortic endothelial cells in vitro after thrombin treatment: Observation with video-enhanced contrast microscopy.  Thromb Res . 1998;  91 15-21
    CrossrefPubMedGoogle Scholar
  • 192 Qi J, Goralnick S, Kreutzer D L. Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells.  Blood . 1997;  90 3595-3602
    PubMedGoogle Scholar
  • 193 Kaplan K L, Mather T, DeMarco L, Solomon S. Effect of fibrin on endothelial cell production of prostacyclin and tissue plasminogen activator.  Arteriosclerosis . 1989;  9 43-49
    PubMedGoogle Scholar
  • 194 Kadish J L, Butterfield C E, Folkman J. The effect of fibrin on cultured vascular endothelial cells.  Tissue Cell . 1979;  11 99-108
    CrossrefPubMedGoogle Scholar
  • 195 Ribes J A, Francis C W, Wagner D D. Fibrin induces release of von Willebrand factor from endothelial cells.  J Clin Invest . 1987;  79 117-123
    PubMedGoogle Scholar
  • 196 Eguchi H, Ikeda H, Murohara T. Endothelial injuries of coronary arteries distal to thrombotic sites: Role of adhesive interaction between endothelial P-selectin and leukocyte sialyl LewisX.  Circ Res . 1999;  84 525-535
    PubMedGoogle Scholar
  • 197 Suzuki H, Abe K, Tojo S. A change of P-selectin immunoreactivity in rat brain after transient and permanent middle cerebral artery occlusion.  Neurol Res . 1998;  20 463-469
    PubMedGoogle Scholar
  • 198 Connolly Jr S E, Winfree C J, Prestigiacomo C J. Exacerbation of cerebral injury in mice that express the P-selectin gene: Identification of P-selectin blockade as a new target for the treatment of stroke.  Circ Res . 1997;  81 304-310
    PubMedGoogle Scholar
  • 199 Sawa H, Fujii S, Sobel B E. Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis.  Arterioscler Thromb . 1992;  12 1507-1515
    PubMedGoogle Scholar
  • 200 Lang I M, Marsh J J, Olman M A. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli.  Circulation . 1994;  89 2715-2721
    CrossrefPubMedGoogle Scholar
  • 201 Lang I M, Moser K M, Schleef R R. Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism.  Arterioscler Thromb Vasc Biol . 1998;  18 808-815
    PubMedGoogle Scholar
  • 202 Wakefield T W, Strieter R M, Wilke C A. Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules [published erratum appears in Arterioscler Thromb Vasc Biol 1995;15:550].  Arterioscler Thromb Vasc Biol . 1995;  15 258-268
    PubMedGoogle Scholar
  • 203 Wakefield T W, Strieter R M, Downing L J. P-selectin and TNF inhibition reduce venous thrombosis inflammation.  J Surg Res . 1996;  64 26-31
    CrossrefPubMedGoogle Scholar
  • 204 Wakefield T W, Strieter R M, Prince M R, Downing L J, Greenfield L J. Pathogenesis of venous thrombosis: A new insight.  Cardiovasc Surg . 1997;  5 6-15
    PubMedGoogle Scholar
  • 205 Downing L J, Wakefield T W, Strieter R M. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis.  J Vasc Surg. 1997;  25 816-827 828
    CrossrefPubMedGoogle Scholar